Gown et al. [21] have reported that a normalized scoring method that subtracts the score for non-neoplastic cells from that for tumor cells reduces the false-positive rate from 31% to 5% in assessing HER2 IHC results for breast cancer. This evidence concerns the gene ERBB2 and breast cancer.